Tissue inhibitor of metalloproteinase-3 expression affects clinicopathological features and prognosis of aflatoxin B1-related hepatocellular carcinoma

Table 5 Univariable Cox proportional hazard regression survival analysis

	OS		RFS
Variable	HR (95%CI)	P value	HR (95%CI)	P value
Age (years), ≥ 49 vs < 49	1.06 (0.77-1.47)	0.72	1.01 (0.71-1.44)	0.97
Gender, male vs female	0.93 (0.64-1.35)	0.68	0.89 (0.59-1.32)	0.55
Race, Han vs others	0.95 (0.69-1.31)	0.76	0.80 (0.58-1.32)	0.27
Smoking, yes vs no	0.70 (0.48-1.03)	0.07	0.57 (0.36-0.89)	0.01
Drinking, yes vs no	0.74 (0.51-1.07)	0.11	0.63 (0.41-0.96)	0.03
HBV, positive vs negative	1.22 (0.86-1.74)	0.27	1.48 (0.99-2.19)	0.05
HCV, positive vs negative	0.85 (0.56-1.30)	0.46	0.97 (0.62-1.50)	0.89
AFP, positive vs negative	2.93 (2.03-4.24)	1.18 × 10-8	2.63 (1.75-3.95)	3.04 × 10-6
AFB1 exposure, high vs low	3.00 (2.06-4.36)	8.43 × 10-9	3.41 (2.25-5.18)	8.67 × 10-9
Tumor size (cm), > 5 vs ≤ 5	2.70 (1.85-3.93)	2.63 × 10-7	2.50 (1.65-3.77)	1.37 × 10-5
ES grade, III-IV vs I-II	1.79 (1.29-2.49)	5.55 × 10-4	1.60 (0.79-2.30)	0.01
TNM stage, II vs I	1.57 (0.97-2.53)	0.06	1.35 (0.79-2.30)	0.27
TNM stage, III vs I	5.95 (3.56-9.94)	1.01 × 10-11	4.29 (2.48-7.41)	1.92 × 10-7
Liver cirrhosis, yes vs no	1.02 (0.72-1.44)	0.93	1.17 (0.79-1.74)	0.43
MVD, high vs low	2.87 (2.06-4.02)	6.84 × 10-10	3.40 (2.34-4.96)	1.82 × 10-10
PVTT, positive vs negative	2.30 (1.62-3.28)	4.06 × 10-6	2.43 (1.68-3.53)	2.95 × 10-6
MVI, positive vs negative	2.48 (1.75-3.50)	2.56 × 10-7	2.53 (1.76-3.64)	5.63 × 10-7
TIMP3, LTE vs HTE	2.92 (2.19-4.09)	4.10 × 10-10	2.34 (1.63-3.38)	4.80 × 10-6

OS: Overall survival; HR: Hazard ratio; RFS: Recurrence-free survival; HCV: Hepatitis C virus; HBV: Hepatitis B virus; AFP: Alpha fetoprotein; ES: Edmondson and Steiner; TNM: Tumor node metastasis; MVD: Microvessel density; PVTT: Portal vein tumor thrombus; MVI: Microvessel infiltration; LTE: Low TIMP3 expression; HTE: High TIMP3 expression; AFB1: Aflatoxin B1.